Medicenna Therapeutics Corp is Shariah compliant. The company’s financials pass three standards and fail in two.
Ad
MDNA – Medicenna Therapeutics Corp
Compliant
★★★☆☆
- Biotechnology & Medical Research
- Toronto Stock Exchange
- July 16, 2022
$58,580,297
Market cap
-
Revenue Growth
BUY
Analysts' Rating
AAOIFI
S&P
DJIM
FTSE
MSCI
AAOIFI
AAOIFI ✓
| Debt ÷ Market cap (MC) | 0.05% | ✓ |
| Non-Compliant Assets ÷ MC | 13.61% | ✓ |
S&P
S&P ✓
| Debt ÷ 36 mo MC | 0.02% | ✓ |
| Cash ÷ 36 mo MC | 19.76% | ✓ |
| AR ÷ 36 mo MC | % |
DJIM
DJIM ✓
| Debt ÷ 24 mo MC | 0.02% | ✓ |
| Cash ÷ 24 mo MC | 15.19% | ✓ |
| AR ÷ 24 mo MC | % |
FTSE
FTSE ✗
| Debt ÷ Assets | 0.08% | ✓ |
| Cash ÷ Assets | 71.89% | ✗ |
| Cash&AR ÷ Assets | 71.89% | ✗ |
MSCI
MSCI ✗
| Debt ÷ Assets | 0.08% | ✓ |
| Cash ÷ Assets | 71.89% | ✗ |
| Cash&AR ÷ Assets | 71.89% | ✗ |
Ad
Recommendation Rating
1.83
1
2
3
4
5
1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL
Analysts’ Price Targets
Mean 7.81
Low: 3.2
High: 12.14
Total Analysts: 7
Company Profile
Medicenna Therapeutics Corp. is a clinical stage immunotherapy company. The Company is primarily engaged in the development and commercialization of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its Bi-functional SuperKine ImmunoTherapies (BiSKITs) platform is designed to enable the ability of Superkines to treat immunologically cold tumors. The Company’s product candidate MDNA55, is an Empowered Superkine developed as a therapeutic for recurrent glioblastoma multiforme (rGBM), a fatal form of brain cancer. MDNA11, an IL-2 Superkine that has been fused with human recombinant albumin. The Company has not earned any revenues from its products.
We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan.
Responses